

HEMISPHERX BIOPHARMA INC  
Form 8-K  
April 17, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)

**April 17, 2018 (April 12, 2018)**

**HEMISPHERX BIOPHARMA, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**                      **0 - 27072**      **52-0845822**  
(state or other jurisdiction    (Commission (I.R.S. Employer  
of incorporation)              File Number) (Identification No.)

**860 N. Orange Avenue, Suite B, Orlando, FL 32801**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(215) 988-0080**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 12, 2018, the Company's Board of Directors, at the recommendation of the Compensation Committee and based upon the Company's recent accomplishments, awarded options to all Company employees and Directors. The options are exercisable for a 10 year period and vest over three years from the date of issuance, with one third of each such option vesting on the first, second and third anniversary of the date of its issuance. The exercise price of the options is \$0.38 per share, the closing price of the Company's common stock on the date of the Board's award. The following named executive officers received options to purchase the following number of shares: Thomas K. Equels, CEO and President, 125,000 shares, Adam Pascale, CFO, 75,000 shares, and Peter Rodino, Executive Director Government Relations, General Counsel, & Secretary, 100,000 shares.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEMISPHERX  
BIOPHARMA, INC.

April 17, 2018 By: */s/ Thomas K. Equels*  
Thomas K. Equels, CEO

